Citations

Showing 10 of 108162 citations.

Genome-wide analysis of 944 133 individuals provides insights into the etiology of haemorrhoidal disease
Zheng, Tenghao , Ellinghaus, David , Juzėnas, Simonas , Cossais, François , Burmeister, Greta , Mayr, Gabriele , Jørgensen, Isabella Friis , Teder‐Laving, Maris , Skogholt, Anne Heidi , Chen, Sisi , Strege, Peter R. , Ito, Go , Banasik, Karina , Bokelmann, Frank, Buch, Stephan , Clausnitzer, Hartmut, Degenhardt, Frauke , Doniec, Marek J., Erikstrup, Christian , Förster, Michael , Frey, Norbert , Fritsche, Lars G. , Gabrielsen, Maiken E. , Gräßle, Tobias , Gsur, Andrea , Hampe, Jochen , Hendricks, Alexander , Hinz, Sebastian , Jongen, Johannes , Junker, Ralf, Karlsen, Tom H. , Hemmrich‐Stanisak, Georg , Kruis, Wolfgang , Kupčinskas, Juozas , Laubert, Tilman , Rosenstiel, Philip , Röcken, Christoph , Laudes, Matthias , Leendertz, Fabian H. , Limperger, Verena , Margetis, Nikolaos, Mätz‐Rensing, Kerstin, Németh, Christopher Georg , Ness‐Jensen, Eivind , Nowak‐Göttl, Ulrike, Pandit, Anita , Pedersen, Ole Birger , Peleikis, H.-G., Peuker, Kenneth , Rodríguez, Cristina Leal , Schniewind, Bodo, Schulzky, Martin, Skiecevičienė, Jurgita , Tepel, Jürgen, Thomas, Laurent F. , Uellendahl-Werth, Florian , Ullum, Henrik , Vogel, Ilka, Völzke, Henry , Schönfels, Witigo von , Vanderwerff, Brett , Wilking, Julia, Wittig, Michael , Zeißig, Sebastian , Zobel, Myrko, Zawistowski, Matthew , Vacic, Vladimir, Sazonova, Olga V. , Noblin, Elizabeth S., Farrugia, Gianrico , Kahlke, Volker, Schafmayer, Clemens , D’Amato, Mauro , Datz, Christian , Forster, Michael , Gsur, Andrea , Hampe, Jochen , Röcken, Christoph , Ness-Jensen, Eivind , Rühlemann, Malte Christoph , Farrugia, Gianrico , D'Amato, Mauro , Franke, André , Ellinghaus, David , Zheng, Tenghao , Strege, Peter R , Erikstrup, Christian , Kupcinskas, Juozas , Becker, Thomas S , Brunak, Søren , Esko, Tõnu , Groß, Justus , Hveem, Kristian , Lieb, Wolfgang , Fersen, Lorenzo von , Sazonova, Olga, Beyder, Arthur , Wedel, Thilo

Mayo Clinic

Gut | April 22, 2021 | Volume: 70 | Issue: 8 | Pages: 1538-1549

10.1136/gutjnl-2020-323868 | PMID 33888516 Get It

Objective Haemorrhoidal disease (HEM) affects a large and silently suffering fraction of the population but its aetiology, including suspected genetic predisposition, is poorly understood. We report the first genome-wide association study (GWAS) meta-analysis to identify genetic risk factors for HEM to date. Design We conducted a GWAS meta-analysis of 218 920 patients with HEM and 725 213 controls of European ancestry. Using GWAS summary statistics, we performed multiple genetic correlation analyses between HEM and other traits as well as calculated HEM polygenic risk scores (PRS) and evaluated their translational potential in independent datasets. Using functional annotation of GWAS results, we identified HEM candidate genes, which differential expression and coexpression in HEM tissues were evaluated employing RNA-seq analyses. The localisation of expressed proteins at selected loci was investigated by immunohistochemistry. Results We demonstrate modest heritability and genetic correlation of HEM with several other diseases from the GI, neuroaffective and cardiovascular domains. HEM PRS validated in 180 435 individuals from independent datasets allowed the identification of those at risk and correlated with younger age of onset and recurrent surgery. We identified 102 independent HEM risk loci harbouring genes whose expression is enriched in blood vessels and GI tissues, and in pathways associated with smooth muscles, epithelial and endothelial development and morphogenesis. Network transcriptomic analyses highlighted HEM gene coexpression modules that are relevant to the development and integrity of the musculoskeletal and epidermal systems, and the organisation of the extracellular matrix. Conclusion HEM has a genetic component that predisposes to smooth muscle, epithelial and connective tissue dysfunction.
National Survey of Patient Factors Associated with Colorectal Cancer Screening Preferences
Zhu, Xuan , Parks, Philip D. , Fischer, Kristin , Griffin, Joan M. , Fischer, Kristin , Griffin, Joan M , Limburg, Paul J. , Weiser, Emily, Rutten, Lila J. Finney

Mayo Clinic

Cancer Prevention Research | April 22, 2021 | Volume: 14 | Issue: 5 | Pages: 603-614

10.1158/1940-6207.capr-20-0524 | PMID 33888515 Get It

AbstractRecommended colorectal cancer screening modalities vary with respect to safety, efficacy, and cost. Better understanding of the factors that influence patient preference is, therefore, critical for improving population adherence to colorectal cancer screening. To address this knowledge gap, we conducted a panel survey focused on three commonly utilized colorectal cancer screening options [fecal immunochemical test or guaiac-based fecal occult blood test (FIT/gFOBT), multi-target stool DNA (mt-sDNA) test, and colonoscopy] with a national sample of U.S. adults, ages 40–75 years and at average risk of colorectal cancer, in November 2019. Of 5,097 panelists invited to participate, 1,595 completed the survey (completion rate, 31.3%). Our results showed that when presented a choice between two colorectal cancer screening modalities, more respondents preferred mt-sDNA (65.4%) over colonoscopy, FIT/gFOBT (61%) over colonoscopy, and mt-sDNA (66.9%) over FIT/gFOBT. Certain demographic characteristics and awareness of and/or experience with various screening modalities influenced preferences. For example, uninsured people were more likely to prefer stool-based tests over colonoscopy [OR, 2.53; 95% confidence interval (CI), 1.22–5.65 and OR, 2.73; 95% CI, 1.13–7.47]. People who had heard of stool-based screening were more likely to prefer mt-sDNA over FIT/gFOBT (OR, 2.07; 95% CI, 1.26–3.40). People who previously had a stool-based test were more likely to prefer FIT/gFOBT over colonoscopy (OR, 2.75; 95% CI, 1.74–4.41), while people who previously had a colonoscopy were less likely to prefer mt-sDNA or FIT/gFOBT over colonoscopy (OR, 0.39; 95% CI, 0.24–0.63 and OR, 0.40; 95% CI, 0.26–0.62). Our survey demonstrated broad patient preference for stool-based tests over colonoscopy, contrasting the heavy reliance on colonoscopy for colorectal cancer screening in clinical practice and highlighting the importance of considering patient preference in colorectal cancer screening recommendations.Prevention Relevance:Our national survey demonstrated broad patient preference for stool-based tests over colonoscopy, contrasting the heavy reliance on colonoscopy for colorectal cancer screening in clinical practice and highlighting the importance of considering patient preference in colorectal screening recommendations.
State of the Art: Management of Barrett’s Esophagus Related Dysplasia and Neoplasia—Which Patient and What Therapy?
Dhaliwal, Lovekirat , Iyer, Prasad G.

Mayo Clinic

Foregut: The Journal of the American Foregut Society | April 22, 2021 | Volume: 1 | Issue: 1 | Pages: 68-77

10.1177/2634516121993260 Get It

Endoscopic eradication therapy (EET) is safe and effective in the management of Barrett’s esophagus (BE) related dysplasia and early adenocarcinoma. EET includes endoscopic resection of the visible lesions followed by ablation to eradicate the residual Barrett’s epithelium. Techniques available for endoscopic resection include cap-based endoscopic mucosal resection and endoscopic submucosal dissection. Ablative therapies such as RFA, cryoablation and APC are used for the eradication of dysplastic BE and to prevent progression to EAC. Complete remission of intestinal metaplasia is the goal of EET. Post-treatment endoscopic surveillance is recommended to detect recurrence of metaplasia/dysplasia, mostly at the gastroesophageal junction.
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515)
Cash, Thomas F. , Fox, Elizabeth , Liu, Xiaowei , Weigel, Brenda J. , Wetmore, Cynthia, Cash, Thomas , Reid, Joel M. , Minard, Charles G. , Scheck, Adrienne C.

Mayo Clinic

Pediatric Blood & Cancer | April 22, 2021 | Volume: 68 | Issue: 9 | Pages: No page available

10.1002/pbc.29065 | PMID 33881209 Get It

AbstractBackgroundPrexasertib (LY2606368) is a novel, second‐generation, selective dual inhibitor of checkpoint kinase proteins 1 (CHK1) and 2 (CHK2). We conducted a phase 1 trial of prexasertib to estimate the maximum‐tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), to define and describe the toxicities, and to characterize the pharmacokinetics (PK) of prexasertib in pediatric patients with recurrent or refractory solid and central nervous system (CNS) tumors.MethodsPrexasertib was administered intravenously (i.v.) on days 1 and 15 of a 28‐day cycle. Four dose levels, 80, 100, 125, and 150 mg/m2, were evaluated using a rolling‐six design. PK analysis was performed during cycle 1. Tumor tissue was examined for biomarkers (CHK1 and TP53) of prexasertib activity.ResultsThirty patients were enrolled; 25 were evaluable. The median age was 9.5 years (range: 2‐20) and 21 (70%) were male. Twelve patients (40%) had solid tumors and 18 patients (60%) had CNS tumors. There were no cycle 1 or later dose‐limiting toxicities. Common cycle 1, drug‐related grade 3/4 toxicities (> 10% of patients) included neutropenia (100%), leukopenia (68%), thrombocytopenia (24%), lymphopenia (24%), and anemia (12%). There were no objective responses; best overall response was stable disease in three patients for five cycles (hepatocellular carcinoma), three cycles (ependymoma), and five cycles (undifferentiated sarcoma). The PK appeared dose proportional across the 80‐150 mg/m2 dose range.ConclusionsAlthough the MTD of prexasertib was not defined by this study, 150 mg/m2 administered i.v. on days 1 and 15 of a 28‐day cycle was determined to be the RP2D.
Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials
Panés, Julián , Vermeire, Séverine , Dubinsky, Marla C. , Loftus, Edward V. , Lawendy, Nervin, Wang, Wenjin , Salese, Leonardo , Su, Chinyu , Modesto, Irene , Colombel, J F. , Loftus, Edward V , Panes, Julian , Vermeire, Séverine , Guo, Xiang , Colombel, Jean‐Frédéric

Mayo Clinic

Journal of Crohn's and Colitis | April 22, 2021 | Volume: 15 | Issue: 11 | Pages: 1852-1863

10.1093/ecco-jcc/jjab065 | PMID 33884415 Get It

Abstract Background and Aims Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. Here, we evaluate the efficacy and safety of tofacitinib re-treatment following treatment interruption in patients with ulcerative colitis. Methods Here, patients with clinical response to tofacitinib 10 mg b.d. induction therapy were randomised to receive placebo in OCTAVE Sustain. Those experiencing treatment failure after Week 8 of OCTAVE Sustain entered OCTAVE Open and re-initiated tofacitinib 10 mg b.d. [re-treatment subpopulation]; efficacy and safety data are presented up to Month 36 of OCTAVE Open. Results Median time to treatment failure following interruption was 169 (95% confidence interval [CI], 94.0–179.0) and 123 [95% CI, 91.0–168.0] days for induction remitters, and induction responders but non-remitters, respectively. Following re-treatment with tofacitinib, rates (non-responder imputation after a patient discontinued; latest observation carried forward imputation after a patient advanced to a subsequent study [NRI-LOCF]) of clinical response, remission, and endoscopic improvement were 74.0%, 39.0%, and 55.0% at Month 2, and 48.5%, 37.4%, and 42.4% at Month 36, respectively. Among induction remitters and induction responders but non-remitters, clinical response rates at Month 36 were 60.6% and 42.4% [NRI-LOCF], respectively. Efficacy was recaptured regardless of prior tumour necrosis factor inhibitor failure status. The safety profile of tofacitinib 10 mg b.d. re-treatment was consistent with the overall cohort and demonstrated no new safety risks associated with exposure of ≤36 months. Conclusions Median time to treatment failure was numerically higher in induction remitters versus induction responders but non-remitters. Following treatment interruption, efficacy was safely and successfully recaptured with tofacitinib 10 mg b.d. re-treatment in a substantial proportion of patients [ClinicalTrials.gov:NCT01458574;NCT01470612].
Introducing Lifestyle Medicine Within the Mayo Clinic Alix School of Medicine in Arizona
Drost, Jennifer M. , Lucas, Pauline H., Patchett, David , Hatley, Melissa R., Scales, Robert , Patchett, David C, Johnson, Daniel C, Lucas, Pauline , Johnson, Daniel

Mayo Clinic

American Journal of Lifestyle Medicine | April 22, 2021 | Volume: 15 | Issue: 6 | Pages: 612-618

10.1177/15598276211007824 | PMID 34916881 Get It

Purpose: High-value care is becoming increasingly important as the United States shifts toward a more sustainable health care system. Lifestyle medicine (LM) may be the highest-value model of care. Surprisingly, however, it is taught in a minority of medical schools. In this article, we describe a pilot project of introducing a brief LM course taught within the Mayo Clinic Alix School of Medicine in Arizona. The main purpose of the course was to introduce the students to LM as a specialty practice and to provide students with foundational knowledge of the pillars of LM. Results: Students reported improved personal health habits and increased confidence in LM competencies.
Alpha‐Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure
Singer, Wolfgang , Schmeichel, Ann M., Schmelzer, James D., Sletten, David M., Gehrking, Tonette L., Gehrking, Jade A., Olson, Anita D., Suarez, Mariana, Misra, Pinaki , Low, Phillip A. , Suarez, Mariana D., Misra, Pinaki P, Singer, Wolfgang , Misra, Pinaki , Shahnawaz, Mohammad , Soto, Claudio A.

Mayo Clinic

Annals of Neurology | April 22, 2021 | Volume: 89 | Issue: 6 | Pages: 1212-1220

10.1002/ana.26089 | PMID 33881777 Get It

Objective To explore the role of alpha‐synuclein (αSyn) oligomers and neurofilament light chain (NfL) in cerebrospinal fluid (CSF) of patients with pure autonomic failure (PAF) as markers of future phenoconversion to multiple system atrophy (MSA). Methods Well‐characterized patients with PAF (n = 32) were enrolled between June 2016 and February 2019 at Mayo Clinic Rochester and followed prospectively with annual visits to determine future phenoconversion to MSA, Parkinson's disease (PD), or dementia with Lewy bodies (DLB). ELISA was utilized to measure NfL and protein misfolding cyclic amplification (PMCA) to detect αSyn oligomers in CSF collected at baseline. Results Patients were followed for a median of 3.9 years. Five patients converted to MSA, 2 to PD, and 2 to DLB. NfL at baseline was elevated only in patients who later developed MSA, perfectly separating those from future PD and DLB converters as well as non‐converters. ASyn‐PMCA was positive in all but two cases (94%). The PMCA reaction was markedly different in five samples with maximum fluorescence and reaction kinetics previously described in MSA patients; all of these patients later developed MSA. Interpretation αSyn‐PMCA is almost invariably positive in the CSF of patients with PAF establishing this condition as α‐synucleinopathy. Both NfL and the magnitude and reaction kinetics of αSyn PMCA faithfully predict which PAF patients will eventually phenoconvert to MSA. This finding has important implications not only for prognostication, but also for future trials of disease modifying therapies, allowing for differentiation of MSA from Lewy body synucleinopathies before motor symptoms develop. ANN NEUROL 2021;89:1212–1220
Complementary and Alternative Medicine Use by Patients From the Gulf Region Seen in the International Practice of a Tertiary Care Medical Center
Kebede, Esayas B., Tan, Judy, Iftikhar, Salma , Lebdeh, Haitham S. Abu, Duggirala, Murali K. , Ghosh, Amit K. , Croghan, Ivana T. , Jenkins, Sarah M. , Mahapatra, Saswati , Bauer, Brent A. , Wahner‐Roedler, Dietlind L. , Abu Lebdeh, Haitham S, Mahapatra, Saswati

Mayo Clinic

Global Advances in Health and Medicine | April 22, 2021 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/21649561211010129 | PMID 33996270 Get It

Background Patients from various countries may have unique patterns of using complementary and alternative medicine (CAM) and unique reasons for using it. Objective Our objective was to assess the use of CAM among patients from the Gulf region attending the Executive and International Health Program of the Department of General Internal Medicine at Mayo Clinic in Rochester, Minnesota. Methods This cross-sectional survey was administered to all patients who were from the Gulf region and were undergoing outpatient evaluation in the Executive and International Health Program. After their initial medical evaluation by a physician, the patients were invited to anonymously complete the modified International Complementary and Alternative Medicine Questionnaire. Results The survey was completed by 69 patients (41 women, 27 men; mean age, 45.4 years). The most frequently seen providers for CAM treatments were physicians (71.0% of patients), spiritual healers (29.0%), and chiropractors (20.3%). CAM treatments most frequently received from a physician were massage therapy (51.0%), hijama (38.8%), spiritual healing (24.5%), and acupuncture or herbs (16.3%). The most frequently used dietary supplements were ginger (42.0%), bee products (30.4%), and garlic (27.5%). The most common self-help therapies were prayers for health (68.1%), meditation (15.9%), and relaxation techniques (11.6%). CAM therapy, including visits to CAM providers, was used by 92.8% of patients. CAM was mainly used to improve well-being and long-term health conditions rather than for acute illnesses. Conclusion The use of CAM was high among our patients from the Gulf region, and the CAM therapies used by this population differed from the ones used by US patients. Physicians providing care to patients from the Gulf region should be aware of how the use of CAM may affect the care needs of these patients.
Facilitating End-of-Life Interaction Between Patients With Severe Communication Impairment and Their Families
Chandregowda, Adithya , Stierwalt, Julie A. G., Clark, Heather M. , Clark, Heather M

Mayo Clinic

Perspectives of the ASHA Special Interest Groups | April 21, 2021 | Volume: 6 | Issue: 3 | Pages: 649-653

10.1044/2021_persp-20-00282 Get It

Purpose The purpose of this report is to promote conversation among medical speech-language pathologists (SLPs) about their role in facilitating family–patient interaction involving patients who acutely encounter the end-of-life (EOL) phase and have severe communication impairment. Case Report We provide self-reflections from our own clinical practice, pertinent literature review, and medical chart review of a relevant patient to serve as a catalyst for such discussion. Reflections We share a preliminary handout containing strategies that SLPs could provide family members of patients who have encountered an EOL phase and have severe communication impairment (e.g., global aphasia) and reduced alertness level. Clinical Implications SLPs can play an important role in facilitating EOL patient–family interaction and alleviate suffering even when patients have severe communication impairment.